Stay updated on Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.9%
- Check21 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check57 days agoChange DetectedThe webpage has been updated to include new information about the study of pembrolizumab in treating metastatic melanoma, including details on laboratory biomarker analysis and quality-of-life assessments. Additionally, the principal investigator's name has been clarified, and the revision number has been updated.SummaryDifference55%
- Check64 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 15, 2025.SummaryDifference0.4%
Stay in the know with updates to Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial page.